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Background: Influenza A(H1N1) causes serious complications in immunocompromised
patients. The efficacy of seasonal vaccination in these patients has been questioned.
Aim: To describe two outbreaks of influenza A(H1N1) in immunocompromised patients.
Methods: Two outbreaks of influenza A(H1N1) occurred in our institution: on the kidney
transplant ward in 2014 including patients early after kidney or simultaneous pancrease
kidney transplantation, and on the oncology ward in 2016 including patients receiving
chemotherapy for malignant tumours. Factors leading to these outbreaks and the clinical
efficacy of seasonal influenza vaccination were analysed.
Findings: Altogether 86 patients were exposed to influenza A(H1N1) during the outbreaks,
among whom the seasonal influenza vaccination status was unknown in 10. Only three out
of 38 vaccinated patients were infected with influenza A(H1N1), compared with 20 out of
38 unvaccinated patients (P ¼ 0.02). The death of one out of 38 vaccinated patients was
associated with influenza, compared with seven out of 38 unvaccinated patients
(P ¼ 0.06). Shared factors behind the two outbreaks included outdated facilities not
designed for the treatment of immunosuppressed patients. Vaccination coverage among
patients was low, between 40% and 70% despite vaccination being offered to all patients
free of charge. Vaccination coverage of healthcare workers on the transplant ward was
low (46%), but, despite high coverage on the oncology ward (92%), the outbreak occurred.
Conclusion: Seasonal influenza vaccination was clinically effective with both a reduced
risk of influenza infection and a trend towards reduced mortality in these immunocom-
promised patients. Several possible causes were identified behind these two outbreaks,
requiring continuous awareness in healthcare professionals to prevent further outbreaks.
ª 2017 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.tation and Liver Surgery,
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Seasonal influenza vaccination has been recommended for
high-risk patients for years, but since the influenza A(H1N1)
pandemic in 2009, general awareness has increased, and
several studies have addressed the serious consequences ofLtd. All rights reserved.
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recipients of solid-organ transplantation [1,2]. During the 2009
pandemic, serious complications were recorded in transplant
recipients infected with influenza A(H1N1), among whom
pneumonia was reported in 30%, admission to intensive care
unit (ICU) in 16e20%, and mortality in 4e8% of patients [2,3].
Increased rates of complications have similarly been reported
in other immunocompromised patient groups, such as haema-
topoietic stem cell transplant recipients and patients with solid
tumours, with reported mortality rates of w6e10% [4,5]. By
comparison, in healthy individuals the mortality of influenza
A(H1N1) is reported as 0e2% among hospitalized patients, and
the risk of ICU admission about 10e20% among hospitalized
patients [6e9].
Although seasonal influenza vaccination is recommended for
high-risk groups, the efficacy of vaccination has been ques-
tioned in immunocompromised patients, with seroconversion
rates barely reaching 50% in several studies including solid-
organ transplant recipients, patients with end-stage renal
disease, or patients receiving chemotherapy [10e16].
We recently described a serious outbreak of influenza
A(H1N1) in a kidney transplant unit [17]. In addition to this
outbreak, another serious outbreak of influenza A(H1N1)
occurred in our institution in the oncology department in 2016.
Factors leading to these serious outbreaks were analysed
thoroughly, and several common factors could be identified in
these outbreaks despite the two somewhat different types of
patient groups. The aim of this study was to describe the fac-
tors leading to these two serious influenza A(H1N1) outbreaks
in a large tertiary hospital, and to describe the protective ef-
fect of vaccination observed in immunocompromised patients.
Methods
Helsinki University Hospital supplies tertiary care for a
population ofw1.5 million inhabitants, and serves the whole of
Finland (populationw5.5 million) for certain special treatment
services, such as solid-organ transplantation. Annually w250
kidney transplantations are performed in the transplant unit,
of which 15e20 are simultaneous pancreasekidney (SPK)
transplantations.
Approximately 1000 patients are admitted to the oncology
ward per year, half of whom are treated for lymphoma. The
average stay is four or five days. Yearly, 25e35 autologous
transplants are performed.
Primary immunosuppression after kidney or SPK trans-
plantation is a combination of cyclosporine or tacrolimus,
mycophenolate, and steroids. Patients with higher immuno-
logical risk or recipients of SPK receive induction with basilix-
imab or anti-thymocyte globulin. After kidney transplantation,
patients remain hospitalized for about 10e21 days, after which
they return for follow-up to their own district hospital. In
addition to postoperative treatment early after trans-
plantation, the kidney transplant ward also includes patients
with complications after transplantation (such as acute
rejection, or surgical or infectious complications). Due to
ongoing renovations in the hospital facilities, the kidney
transplant service was temporarily located in a ward not
designed for the treatment of immunosuppressed patients. The
ward had 16 patient beds: four three-bed rooms with shared
sanitation, and two two-bed rooms with bathrooms, but nosingle rooms. Rooms were narrow and space between beds was
60e90 cm in width. Patients shared a common dining room. In
addition to inpatients on the ward, it was also used for frequent
outpatient visits for patients in early stages after trans-
plantation and for patients travelling from other parts of the
country.
The oncology ward e one of the two wards in the oncology
department built in the 1960s e has 18 patient beds and two
beds for daycare patients. The ward specializes in treating
adolescents and young adults with lymphoma, testicular can-
cer, osteosarcoma and Ewing sarcoma together with lymphoma
patients of all ages. Patients receiving high-dose chemotherapy
with autologous stem cell transplantation as a part of their
treatment for lymphoma, testicular cancer and Ewing sarcoma
are cared for on the ward. Patients with other cancers are
mainly treated for cancer therapy-induced complications and
for need of immediate palliative care. There are five single
rooms with their own toilet; only one has its own bathroom.
Five rooms house three beds, for which there are four toilets
and three showers on the corridor. The young patients espe-
cially have been encouraged to use the dayroom to find peer
support.
Influenza A was diagnosed with a qualitative real-time po-
lymerase chain reaction from nasopharyngeal swabs, as
described [18]. Seasonal influenza vaccination is recommended
for all patients at risk of infection, including end-stage renal
disease patients on dialysis, patients after kidney trans-
plantation, and patients receiving treatment for cancer, and
the vaccination is provided free of charge. Vaccination is also
recommended for all healthcare professionals free of charge.
Seasonal vaccine in the 2013e2014 campaign included three
antigens: influenza A/California/7/2009 (H1N1)-like virus,
influenza A/Texas/50/2012 (H3N2)-like virus, and influenza B/
Massachusetts/2/2012-like virus, and was either Fluarix
(GlaxoSmithKline, Brentford, UK), recommended for patients
aged >65 years, or Vaxigrip (Sanofi Pasteur MSD, Brussels,
Belgium) for younger patients, both inactivated trivalent vac-
cines without adjuvant. The seasonal vaccine in the 2015e2016
campaign was Vaxigrip (Sanofi Pasteur MSD, Brussels, Belgium),
containing three antigens: A/California/7/2009 (H1N1)pdm09-
like virus, A/Switzerland/9715293/2013 (H3N2)-like virus, and
B/Phuket/3073/2013-like virus.
Differences in variable distributions between the two groups
were analysed using the non-parametric ManneWhitney U-test
(continuous variables), or Fisher’s exact test (categorical var-
iables). The calculations were performed with IBM SPSS Sta-
tistics (version 20; IBM Corporation, Somers, NY, USA). Two-
sided P < 0.05 was considered statistically significant.
Results
Description of the outbreaks
The outbreak on the kidney transplant ward has been
described in detail previously [17]. Briefly, in April 2014, alto-
gether 23 patients were treated on the ward during the
outbreak (Table I). After the first positive case, all patients
were tested and seven patients were diagnosed with influenza
A(H1N1). Of the 17 patients who had received adequate sea-
sonal influenza vaccination, two out of 17 tested positive for
influenza (one asymptomatic, one with mild cough). Influenza
Table II
Patients exposed on the oncology ward
Variable Exposed patients with
malignant disease (N ¼ 63)
Mean (range) age (years) 59 (20e87)
Type of cancer
Non-Hodgkin lymphoma 27a
Intestinal 6
Thyroid 6
Prostata 5
Hodgkin lymphoma 4a
Liver 3
Ewing sarcoma 2a
Testicular 2
Other 8b
Seasonal influenza vaccination
coverage of the patients
with known status
21/53 (40%)
Rate of ICU admission among
infected patients
3/16 (19%)
a One patient with non-Hodgkin lymphoma, one patient with Hodgkin
lymphoma, and one patient with Ewing sarcoma had received high-dose
chemotherapy with autologous stem cell transplantation; none of them
had received seasonal influenza vaccination.
b Other types of cancer (one of each): brain, melanoma, breast,
oesophagus, multiple myeloma, ovarian, lung, head and neck.
Table I
Kidney and pancreasekidney transplant patients exposed to
influenza A(H1N1) during the outbreak
Variable Exposed transplant
recipients (N ¼ 23)
Mean (range) age (years) 55 (32e75)
Kidney/SPK recipients 22/1
Seasonal influenza vaccination
coverage pre-transplant
17 (74%)
Transplantation <1 month
before the outbreak
18 (78%)
Rate of ICU admission
among infected patients
3/7 (43%)
SPK, simultaneous pancreasekidney; ICU, intensive care unit.
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three of whom suffered from severe respiratory failure and
died due to acute respiratory distress syndrome despite being
treated with mechanical ventilation in the ICU. Two unvacci-
nated patients suffered from mild viral pneumonitis and
recovered fully.
On the oncology ward in January 2016, five patients and two
members of the personnel on the ward had respiratory symp-
toms simultaneously, and, after the first confirmed case of
influenza A(H1N1), all patients on the ward were tested with
nasopharyngeal swabs. During the outbreak, which occurred in
two waves, a total of 63 patients were exposed, 17 of whom
were diagnosed with influenza A(H1N1). Of the 21 patients who
had received adequate seasonal influenza vaccination, only
one patient was diagnosed with influenza A(H1N1). This patient
had been vaccinated while receiving immune-chemotherapy
(ReCHOP) for aggressive lymphoma. She relapsed at the time
of contracting pneumonia caused by influenza, which pre-
vented starting chemotherapy, and she died of progressive
lymphoma. Of the 32 unvaccinated patients on the oncology
ward, 15 were diagnosed with influenza A(H1N1). Of these 15
patients, three were admitted to ICU and needed mechanical
ventilation, and two out of these three patients died after
10e31 days of treatment in the ICU. In addition, one patient
died on the ward due to pneumonia caused by influenza, and
another unvaccinated patient had to stop chemotherapy
because of influenza-related infection and died due to pro-
gressive lymphoma. The vaccination history of 10 patients
without influenza infection remains unknown. Patients
exposed on the oncology ward are described in Table II.
Analysis of the possible reasons behind the outbreaks
Poor design of the treatment facilities
Both wards were located in old hospital buildings, built in
the 1950s and 1960s, in which modern infection control is not
possible. The oncology ward had 18 patient beds, of which only
five are located in single-bed rooms, and the other five rooms
were three-bed rooms with a short distance between the beds
(90e120 cm). The transplant ward had 16 patient beds, of
which only two rooms included two patient beds; the other
rooms had three patient beds with similarly very short distance
between the beds (90e120 cm). The two-bed rooms had their
own toilet and shower, but the other four rooms (12 patients)
shared two toilets and showers. After the first cases had beendiagnosed, symptomatic patients were rapidly isolated and
cohorted and all the patients on the ward were tested for
influenza with nasopharyngeal swabs. Symptomatic patients
were started on oseltamivir (treatment dose 75 mg twice daily
or adjusted for renal function), and asymptomatic patients
were started on a prophylactic dose of oseltamivir (75 mg once
daily or adjusted for renal function). Both wards were closed
temporarily and no new patients were admitted due to lack of
adequate isolation facilities.
Vaccination coverage of the patients and protective
effect of vaccination
The vaccination coverage of the patients with a known
vaccination history on the oncology ward outbreak was 21 out
of 53 (40%), and 17 out of 23 (74%) on the transplant ward. In
total, 20 out of 38 (53%) of the unvaccinated patients were
diagnosed with influenza A(H1N1), whereas of the vaccinated
patients only three out of 38 (8%) were infected. The relative
risk of influenza infection in the unvaccinated patients was 9.8
(95% confidence interval (CI): 1.4e69.0; P ¼ 0.002). Of the
unvaccinated exposed patients, seven out of 38 (18%) died due
to influenza-related causes, compared to one out of 38 (3%) of
the vaccinated patients. The relative risk of death in the un-
vaccinated patients was 7.0 (95% CI: 0.90e54.2; P ¼ 0.06)
compared to patients with vaccination. If only direct deaths
caused by influenza (pneumonia and respiratory failure) are
included, six out of 38 (16%) of the unvaccinated patients died,
compared to none of the vaccinated patients, with the relative
risk being 13.0 (95% CI: 0.76e223.0; P ¼ 0.07). Table III com-
pares the risk of infection and mortality in vaccinated and
unvaccinated patients. Three patients on the oncology ward
had received high-dose chemotherapy with autologous hae-
matopoietic stem cell transplantation and none of them had
Table III
Outcome of the exposed patients in both influenza A(H1N1) outbreaks
Variable Transplant service 2014 Oncology service 2016 No./total
Infected vs exposed patients 7/23 17/63 24/86
No. of vaccinated patients 17 21a 38
No. of infected patients among vaccinated 2/17 (12%) 1/21 (5%) 3/38 (8%)b
No. of infected patients among unvaccinated 5/6 (83%) 15/32 (47%)a 20/38 (53%)b
Mortality among vaccinated 0/17 1/21 (5%) 1/38 (3%)c
Mortality among unvaccinated 3/6 (50%) 4/32 (13%) 7/38 (18%)c
a The vaccination history of 10 patients exposed on the oncology ward was unknown.
b P ¼ 0.002 for the increased risk of infection in patients with no vaccination vs vaccination.
c P ¼ 0.06 for the increased risk of death in patients with no vaccination vs vaccination.
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were diagnosed with influenza A(H1N1), of whom one died.
Vaccination coverage of the healthcare personnel
On the transplant ward, the vaccination coverage of the
healthcare personnel was alarmingly low: only 46% of the
personnel had received adequate seasonal influenza vaccina-
tion. Eight healthcare workers (five unvaccinated and three
vaccinated) had respiratory tract symptoms. However, they
were not tested for influenza infection. On the oncology ward,
92% of the healthcare personnel had received adequate sea-
sonal influenza vaccination. Of the two unvaccinated em-
ployees with respiratory tract symptoms, influenza A(H1N1)
was diagnosed in one person.Discussion
This report describes the circumstances and events behind
two serious outbreaks of influenza A(H1N1) in immunocom-
promised patients. Although similarities were found between
the outbreaks e most importantly poor, outdated facilities not
designed for the treatment of immunosuppressed patients e
differences were also noted between the outbreaks. In both
outbreaks, the clinical real-world efficacy of seasonal influenza
vaccination was better than described in studies analysing most
often serological response to vaccination. Increased risk of
both influenza A(H1N1) infection and mortality was detected in
unvaccinated patients. The difference was more pronounced in
the kidney transplant recipients, but a similar trend for
increasing mortality was also seen in unvaccinated patients
receiving intensive chemotherapy for cancer.
Although several previous studies have shown poor sero-
logical response to influenza vaccination among recipients of
solid-organ transplantation, patients with end-stage renal
disease, and otherwise immunosuppressed patients, our cur-
rent analysis supports the clinical efficacy of seasonal influenza
vaccination in preventing serious disease. Although it is well
known that serological responses to vaccinations remain poor
in immunosuppressed patients, some studies show that cellular
immune response to influenza vaccine may be comparable to
the healthy population, supporting our findings of clinical ef-
ficacy [10e16,19,20].
When analysing the reasons leading to the outbreaks, some
differences were detected. The vaccination coverage of the
healthcare personnel was high in the oncology ward outbreak,
and exceeded, for example, the US national target of 90% [21].Nevertheless an outbreak occurred, suggesting that other
factors may play a role, most importantly the vaccination
coverage of the patients and the poor facilities on the wards. In
our analyses, the vaccination coverage among kidney and SPK
recipients was 74%, which is similar to vaccination coverage
between 52% and 88% reported in previous studies among solid-
organ transplant recipients [22,23]. Vaccination coverage in
patients with malignant disease in our study was lower
compared to that of transplant recipients (only 40%), yet within
the range of 13e70% reported in other studies in patients with
malignant disease [24e26].
After the outbreaks, several measures were taken in the
transplantation unit to prevent further outbreaks. In 2015 the
transplantation service moved to a new building with modern
facilities and the means for infectious isolation. In addition,
patient and health care personnel education on the importance
of the vaccination was increased, and the process of vacci-
nating transplant and dialysis patients has been simplified with
easy access to vaccination at dialysis units, cancer hospital,
and outpatient clinics. Similarly, the vaccination procedure for
healthcare personnel was simplified in our hospitals, and the
vaccination coverage of the personnel has increased and
reached >90% in the season 2016e2017.
Another possible measure to prevent further outbreaks
would be to introduce the policy to use surgical masks with all
healthcare personnel and visitors, or even patients, as there is
evidence suggesting that the use of surgical masks in all patient
contacts regardless of symptoms or season may reduce the
incidence of respiratory viral infections, especially in stem cell
transplant patients [27e29]. Even before the outbreak, symp-
tomatic visitors were not allowed to visit the patients on either
of the wards, hand disinfection was recommended to all visi-
tors, and a surgical mask was recommended for close contact
for visitors on the oncology ward. The source of influenza
A(H1N1) in both outbreaks remained unidentified, and, despite
the protective measures, visitors may have had a role in
introducing the infection to the wards.
This study had some limitations. First, although some com-
mon possible factors were identified, which could increase the
risk for outbreaks on the wards, causality cannot be concluded
from this retrospective analysis. In addition, patients treated
on the oncology ward were a heterogeneous group of patients
receiving chemotherapy for different types of malignant tu-
mours, and the timing of the vaccination with regard to the
chemotherapy was not adjusted for. It may also be debated
whether patients with immunosuppression early after organ
transplantation and patients receiving chemotherapy can
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within this analysis several similar characteristics were iden-
tified behind these outbreaks, which could potentially be
addressed, leading to improved conditions on the ward to
prevent further outbreaks. The small number of cases in our
analysis did not allow extensive multivariable analyses for the
protective effect of vaccination. However, despite these limi-
tations a clear association was seen in the increased risk of
influenza infection and death due to influenza in the unvacci-
nated patients, supporting the clinical efficacy of seasonal
influenza vaccination also in immunocompromised patients.
In conclusion, we describe two serious outbreaks of influ-
enza A(H1N1) in immunocompromised patients, in whom sea-
sonal influenza vaccination was associated with a reduced risk
for influenza infection and mortality. Several possible causes
were identified behind the outbreaks that require continuous
awareness in healthcare professionals to prevent further
outbreaks.
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